A Phase II RCT [22] investigated the subcutaneously administered anti-IL-17A mAb CJM112 300 mg when added to existing therapy in patients with inadequately controlled moderate to severe asthma, with low serum IgE and BEC. This evidence concerns the gene IL17A and asthma.